1. Health

Flow Cytometry Market Highly Favorable to the Growth Rate By 2030

Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

The global flow cytometry market size is expected to reach USD 7,531.2 million by 2030, registering a CAGR of 7.17% over the forecast period, according to a new report by Grand View Research, Inc. Technological advancements in the technique are introducing new and improved analytical tools, which include the development of microfluidic flow cytometry for Point-of-Care (PoC) testing. Furthermore, the rising prevalence of cancer, immunodeficiency disorders, and infectious diseases is driving the industry. In addition, increasing R&D investments in biopharmaceutical, life science, and biotechnology research activities have led to high demand for flow cytometry instruments. In recent years, a key focus has been on the development of portable microfluidic flow cytometry devices for PoC testing.

Microfluidics and flow cytometry together make a useful tool to measure multiple characteristics of biological samples. For instance, the easy availability of several microfluidics and miniaturized detectors have enabled the creation of microchip-based cytometers, such as optofluidic cytometer, imaging cytometer, and impedance cytometer. The development of microfluidic flow cytometry devices, which are cost-effective, portable, and compact, is beneficial. They are affordable in developing economies, such as Asia & Africa, and are enabling rapid growth in PoC testing applications. Furthermore, improvements in fluorescent dyes and the increasing utility of benchtop cytometers for academic research settings are expected to drive the industry.

Developments in multicolor flow cytometry are accelerating the adoption of the technique in novel drug development activities. For instance, in January 2020, DxFLEX, CE-IVD, a 13-colour clinical flow cytometry system was launched by Beckman Coulter Life Sciences in Europe. Similarly, easy cellular analysis by simultaneous evaluation of several parameters allows extensive use of such devices for contract research purposes. The COVID-19 pandemic also spurred innovations in the technique, as evidenced by the launch of new products in this domain. For instance, in July 2021, Metropolis Healthcare Ltd. launched CoviRisk–TBNK, a simple blood test to detect the risk status of a COVID-19 hospitalized patient.

It helps analyze patients’ need for ICU facilities or ventilation and aids in the reduction of stress on healthcare resources. The test is a flow cytometry-based lymphocyte subset assay and is IVD-approved. Such innovations are anticipated to fuel industry growth in the near future. Moreover, flow cytometry is a significant tool in listing and characterizing immune cells, and is also helpful in recognizing and validating underlying genetic defects. The technique is also used to observe and monitor the immune response of patients after stem cell transplantation, and hence, organ transplantation plays an important role in boosting industry growth. According to the WHO, around 50,000 stem cell transplantations are performed globally every year, and this number is expected to grow in the near future, broadening the scope of applications for the technique.

On the other hand, instruments are highly expensive, and hence, buyers in several developing countries may not be able to afford technologically advanced flow cytometry equipment. These instruments may cost over USD 100,000 and pose significant budgetary constraints for small- & mid-sized hospitals and clinical laboratories. However, some manufacturers, such as Sony, are trying to launch newer instruments using software to automate a number of processes. Such developments would not only improve the usability of the technique but also help bring down the average instrumentation cost–under USD 100,000–in the near future.

Request a free sample copy or view report summary: Flow Cytometry Market Repor

Flow Cytometry Market Report Highlights

  • The instrument product segment held the largest share in 2022 due to technical advancements, as well as increased prevalence of chronic conditions

  • Thecell-based flow cytometry technology dominated the industry in 2022 due to the high demand for early diagnosis and rising awareness about the associated benefits of cell-based assays

  • By application, the clinical segment accounted for the largest revenue share in 2022 owing to increased activities pertaining to infectious diseases, such as influenza, HIV, and COVID-19, among others

  • The academic institutes end-user segment led the market in 2022 owing to increased R&D activities by academic institutes & research centers

  • North America was the leading region in 2022 due to the high implementation of scientifically advanced flow cytometry solutions, high healthcare expenditure, and well-established healthcare infrastructure in the region

  • Asia Pacific is expected to register the fastest CAGR from 2022 to 2030 owing to the extensive growth in the pharmaceutical and biotechnology industries in emerging economies, such as China and India

Access Press Release @ https://www.grandviewresearch.com/press-release/global-flow-cytometry-market

Flow Cytometry Market Segmentation

Grand View Research has segmented the global flow cytometry market based on product, technology, application, end-use, and region:

Flow Cytometry Product Outlook (Revenue, USD Million, 2018 – 2030)

  • Instruments

    • Cell Analyzers

    • Cell Sorters

  • Reagents & Consumables

  • Software

  • Accessories

  • Services

Flow Cytometry Technology Outlook (Revenue, USD Million, 2018 – 2030)

  • Cell-based

  • Bead-based

Flow Cytometry Application Outlook (Revenue, USD Million, 2018 – 2030)

  • Research

    • Pharmaceutical

      • Drug Discovery

      • Stem Cell

      • In Vitro Toxicity

    • Apoptosis

    • Cell Sorting

    • Cell Cycle Analysis

    • Immunology

    • Cell Viability

  • Industrial

  • Clinical

    • Cancer

    • Organ Transplantation

    • Immunodeficiency

    • Hematology

Flow Cytometry End-use Outlook (Revenue, USD Million, 2018 – 2030)

  • Commercial Organizations

    • Biotechnology Companies

    • Pharmaceutical Companies

    • CROs

  • Hospitals

  • Academic Institutes

  • Clinical Testing Labs

Flow Cytometry Regional Outlook (Revenue, USD Million, 2018 – 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Singapore

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • UAE

    • South Africa

    • Saudi Arabia

List of Key Players of Flow Cytometry Market

  • Danaher Corp.

  • Becton, Dickinson, and Company (BD)

  • Sysmex Corp.

  • Agilent Technologies, Inc.

  • Apogee Flow Systems Ltd.

  • Bio-Rad Laboratories, Inc.

  • Thermo Fisher Scientific, Inc.

  • Stratedigm, Inc.

  • DiaSorin SpA

  • Miltenyi Biotec

  • Sony Biotechnology, Inc.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe